Syngene International has become a key player in the global CRAMS industry, driven by strong partnerships with pharmaceutical and biotech companies. As the demand for outsourced research and manufacturing continues to rise, investors are increasingly interested in Syngene International share price targets from 2026 to 2030.
The company’s focus on innovation, biologics expansion, and long-term contracts positions it well for steady growth. In this analysis, we explore the potential share price targets for 2026, 2027, 2028, 2029, and 2030 based on current market trends and business fundamentals.
Syngene International Share Price Target 2026
Syngene International is gaining strong attention from investors due to its consistent growth in the CRAMS (Contract Research and Manufacturing Services) space and partnerships with global pharma companies.
Looking ahead to 2026, the company’s focus on expanding biologics manufacturing and research capabilities could drive steady revenue growth. Based on current fundamentals and industry trends, the first target for Syngene International share price in 2026 is expected to be around ₹490, while a more optimistic scenario could see it reaching ₹530.
Increasing demand for outsourced research, strong parentage of Biocon, and global expansion plans support this positive outlook. However, market volatility and regulatory challenges should also be considered by investors.
Syngene International Share Price Target 2026 Table
| Year | Syngene International Share Price Target 2026 |
| First Target 2026 | Rs 490 |
| Second Target 2026 | Rs 530 |
Syngene International Share Price Target 2027
Syngene International is expected to show steady growth by 2027, driven by its strong presence in contract research, biologics manufacturing, and global partnerships with leading pharma companies.
Based on current expansion plans and increasing demand for outsourcing in the pharmaceutical sector, the share price target for 2027 could range between ₹560 in a moderate scenario.
In a more bullish case, supported by capacity expansion and higher client acquisitions, the stock may reach ₹580 levels. Long-term investors are closely watching its revenue visibility and margin improvement trends, which remain key growth drivers. Overall, Syngene International continues to be a promising player in India’s CRAMS segment.
Syngene International Share Price Target 2027 Table
| Year | Syngene International Share Price Target 2027 |
| First Target 2027 | Rs 560 |
| Second Target 2027 | Rs 580 |
Syngene International Share Price Target 2028
Syngene International share price target for 2028 is expected to reflect the company’s strong position in the contract research and manufacturing services (CRAMS) space, driven by rising global demand from pharmaceutical and biotech companies.
With consistent revenue growth, strategic partnerships, and expansion in research capabilities, the stock may show steady upside in the coming years. The first target for 2028 could be around ₹620, assuming stable market conditions and continued business growth.
In a more optimistic scenario, the second target may reach ₹650 if the company benefits from higher outsourcing trends and improved profit margins. Long-term investors may find Syngene attractive due to its strong fundamentals and global client base.
Syngene International Share Price Target 2028 Table
| Year | Syngene International Share Price Target 2028 |
| First Target 2028 | Rs 620 |
| Second Target 2028 | Rs 650 |
Syngene International Share Price Target 2029
Syngene International share price target for 2029 looks optimistic as the company continues to expand its presence in the contract research and manufacturing space, supported by strong global partnerships and growing demand in the pharmaceutical and biotech sectors.
With consistent revenue growth and strategic investments in innovation, the stock could show steady upward momentum over the long term. Based on current fundamentals and industry trends, the first target for 2029 can be around ₹680, driven by business expansion and margin improvement.
If the company sustains its growth trajectory and global demand remains strong, a second target of ₹720 is achievable. However, investors should also keep an eye on market conditions and sector risks before making long-term decisions.
Syngene International Share Price Target 2029 Table
| Year | Syngene International Share Price Target 2029 |
| First Target 2029 | Rs 680 |
| Second Target 2029 | Rs 720 |
Syngene International Share Price Target 2030
Syngene International has emerged as a strong player in the CRAMS (Contract Research and Manufacturing Services) space, benefiting from rising global outsourcing trends and partnerships with leading pharmaceutical companies.
Looking ahead to 2030, the company’s consistent revenue growth, expansion in biologics, and strong client base could support long-term value creation. Based on current fundamentals and industry growth, the first share price target for 2030 may range around ₹750, driven by steady earnings and capacity expansion.
In a more optimistic scenario, with higher global demand and margin improvement, the second target could reach approximately ₹800. However, investors should also consider risks like global slowdown, regulatory challenges, and currency fluctuations before making long-term decisions.
Syngene International Share Price Target 2030 Table
| Year | Syngene International Share Price Target 2030 |
| First Target 2030 | Rs 750 |
| Second Target 2030 | Rs 800 |
Syngene International Share F.A.Q.
– What does Syngene International do?
Syngene International is a leading contract research and manufacturing company that provides services to global pharmaceutical, biotechnology, and chemical companies.
– Is Syngene International a good long-term investment?
Syngene International is considered a strong long-term investment due to its consistent growth, strong client base, and increasing demand for outsourced research services.
– What factors affect Syngene International share price?
The share price is influenced by revenue growth, global pharma demand, new client deals, R&D expansion, currency fluctuations, and overall market conditions.
– What is the future growth potential of Syngene International?
The company has strong growth potential due to rising global outsourcing trends, expansion in biologics, and partnerships with major pharmaceutical companies.
– Does Syngene International pay dividends?
Yes, Syngene International pays dividends, but it mainly focuses on reinvesting profits for business expansion and long-term growth.
Conclusion
Overall, Syngene International shows promising long-term growth potential backed by a strong business model and increasing global demand for research services. If the company continues to expand its capabilities and maintain strong client relationships, it could deliver consistent returns for investors over the coming years. However, factors like global economic conditions, regulatory changes, and currency fluctuations should also be considered. For long-term investors, Syngene International remains an attractive stock to watch from 2026 to 2030.
Also read:-